KAMADA LTD KMDA
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $180.5M | $161.0M | $142.5M | $129.3M | $103.6M | $133.2M | $127.2M | $114.5M | $102.8M | $77.5M |
| SG&A | — | — | — | — | $12.6M | $10.1M | $9.2M | $8.5M | — | — |
| Operating income | $26.2M | $20.1M | $10.1M | $4.5M | -$696.0K | $19.2M | $22.8M | $19.3M | $7.4M | -$5.5M |
| Net income | $20.2M | $14.5M | $8.3M | -$2.3M | -$2.2M | $17.1M | $22.3M | $22.3M | $6.9M | -$6.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Short-term investments | — | — | — | — | — | $39.1M | $31.2M | — | — | — |
| Total assets | $378.7M | $372.3M | $354.9M | $322.4M | $318.7M | $210.7M | $173.8M | $138.1M | $122.1M | $99.7M |
| Total current liabilities | — | — | — | — | — | $222.0K | — | — | — | — |
| Total equity | $269.1M | $259.5M | $244.0M | $176.0M | $176.8M | $178.6M | $135.3M | $112.4M | $89.5M | $66.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-025934.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |